id stringlengths 1 5 | contents stringlengths 354 1.98k |
|---|---|
17600 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
HIV
From being a near-fatal prognosis, HIV is now a chronic condition with near-normal life expectancy. The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form. |
17601 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The first antiretroviral therapy (ART) started with azidothymidine in the late 90s, which belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class of medications. The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. |
17602 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. |
17603 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The current regimen is a combination of NRTIs, nonnucleoside NRTIs (NNRTI), protease and integrase inhibitors and casts a heavy pill burden, apart from side effects. ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill. |
17604 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. |
17605 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
ART therapy is focused on limiting viral replication at several levels of cell development. NNRTI and NRTI act at the cellular level, protease inhibitors work at the maturation phase, integrase inhibitors at the integration phase of the viral lifecycle.
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. |
17606 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. |
17607 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Truvada is the first approved PrEP (pre-exposure prophylaxis) treatment for those at risk of viral exposure. These work at very early stage of viral exposure and have found high success when taken regularly in the pill form.
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon. |
17608 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
However, treatment resistance to ARTs from prior exposure is an increasing concern in HIV patients. Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon.
Gilead’s several Phase-2 programmes with ART combination are in progress. |
17609 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Gilead’s Lenacapavir, approved last year, is a single-pill treatment regimen for patients with multi-drug resistance to ART regimen. This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon.
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. |
17610 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This formulation also addresses the pill burden with a single pill.
That said, by limiting viral replication, ARTs, by design, cannot cure or lead to remission of HIV. There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon.
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030. |
17611 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
There is hope, though. By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon.
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030.
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. |
17612 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
By pinpointing a cohort of patients whose viral load was under control with limited treatment, researchers have identified broadly neutralising antibodies or bNAbs as a potential cure for HIV. Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon.
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030.
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. |
17613 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Antibodies deal with viruses but fail to do so in HIV infection. By engineering bNAbs in a manner similar to mABs for cancer or vaccines (where antibody reaction to neutered virus generates immune protection), HIV cure may be on the horizon.
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030.
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years. |
17614 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030.
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. |
17615 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Gilead’s several Phase-2 programmes with ART combination are in progress. Studies as recently as February 2023 presented proof of concept — 90 per cent participants showed virological suppression at 26 weeks. Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030.
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. |
17616 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Incidentally, Gilead’s Sovaldi and Harvoni were the first cures for Hepatitis C. The World Health Organization (WHO) aims to eradicate the virus by 2030.
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. Pfizer, Eli lilly, Merck and many others faced failure in the space. |
17617 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. |
17618 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Alzheimer’s
The degenerative disease of the brain has proved to be a difficult challenge for pharmaceutical companies. Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. |
17619 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Leqembi (lecanemab), developed by Eisai in collaboration with Biogen, was the first and only approved drug for Alzheimer’s in July 2023. This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. |
17620 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. |
17621 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
This comes after several failed attempts, and one controversial false start in the recent years.
Alzheimer’s disease is characterised by amyloid beta deposits on brain cells leading to shrinking and loss of cognitive abilities. Despite a clear marker of amyloid plaques and a target area to work on, pharma companies failed to address plaque removal or a statistical improvement in cognitive functioning after plaque removal, till the recent approval. Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. However, with a “traditional” approval for Eisai-partnered lecanemab for Alzheimer’s (compared to accelerated approval for adacanumab), Biogen has the first approved treatment, putting adacanumab on the backburner. |
17622 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. However, with a “traditional” approval for Eisai-partnered lecanemab for Alzheimer’s (compared to accelerated approval for adacanumab), Biogen has the first approved treatment, putting adacanumab on the backburner.
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. |
17623 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Pfizer, Eli lilly, Merck and many others faced failure in the space. The amyloid theory itself was in question.
Biogen’s adacanumab had a peculiar start. The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. However, with a “traditional” approval for Eisai-partnered lecanemab for Alzheimer’s (compared to accelerated approval for adacanumab), Biogen has the first approved treatment, putting adacanumab on the backburner.
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. |
17624 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The company itself stopped development in 2019, but it surprisingly pursued a high-dose study into 2021. Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. However, with a “traditional” approval for Eisai-partnered lecanemab for Alzheimer’s (compared to accelerated approval for adacanumab), Biogen has the first approved treatment, putting adacanumab on the backburner.
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve. |
17625 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Later, FDA approved adacanumab with an accelerated approval for high-dose version, which faced sharp criticism. Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. However, with a “traditional” approval for Eisai-partnered lecanemab for Alzheimer’s (compared to accelerated approval for adacanumab), Biogen has the first approved treatment, putting adacanumab on the backburner.
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve.
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. |
17626 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Three advisers resigned over the approval of the drug that could have cost $56,000 per annum to administer. However, with a “traditional” approval for Eisai-partnered lecanemab for Alzheimer’s (compared to accelerated approval for adacanumab), Biogen has the first approved treatment, putting adacanumab on the backburner.
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve.
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. |
17627 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve.
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success. |
17628 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Cognitive function improvement is a critical marker for Alzheimer’s treatment and lecanemab delivers lower degeneration compared to placebo on this count. The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve.
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success.
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. |
17629 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The treatment reduced clinical decline by 27 per cent at 18 months on clinical dementia scoring and on daily living scale delivered a 37 per cent improvement compared to placebo. As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve.
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success.
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). |
17630 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
As is evident, the development is satisfactory but a lot more progress is left to be made on Alzheimer’s treatment curve.
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success.
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings. |
17631 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Takeaways for Investors
Analysing pharma stocks in the US rests on three factors: drugs about to expire, drugs in ramping up stage and the pipeline. With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success.
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings.
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. |
17632 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
With sharp fall post genericisation, drugs about to expire will be a major overhang for any company, without a portfolio in ramping up stages. Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success.
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings.
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well. |
17633 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Pipeline products cannot really offset absence of products in ramp-up stage, as pipeline assets are given lower probabilities of success. Generally, Phase-I/II/III assets get 10/20/50 per cent probability of success.
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings.
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well.
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. |
17634 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
So a good pharma stock should have low impact from expiries and fairly distributed pipeline. Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings.
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well.
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent. |
17635 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Along such lines, we earlier recommended Novo Nordisk (+140 per cent since July-21) and Abbvie (+27 per cent since Oct-21). We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings.
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well.
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. |
17636 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
We reiterate the recommendation on two stocks which are now trading at 31 times and 12 times FY24 earnings.
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well.
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. |
17637 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Novo Nordisk, with sales ramp-up in weight loss, pill format and weekly injections of GLP-1RA, is well poised to grow even now. The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well.
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. |
17638 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The pipeline will address NASH (untreated liver disease), hematology and other non-diabetic areas as well.
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. While biosimilar launches will impact Keytruda’s sales in 2028, the rate of decline may be lower owing to strong physician preference for Keytruda. |
17639 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. While biosimilar launches will impact Keytruda’s sales in 2028, the rate of decline may be lower owing to strong physician preference for Keytruda.
Another important aspect to consider is the pipeline valuation. |
17640 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Abbvie, despite Humira’s patent loss by end 2023 ($22 revenue billion in 2022) will continue to be powered by Rinvoq and Skyrizi in autoimmune, apart from deep pipeline assets. The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. While biosimilar launches will impact Keytruda’s sales in 2028, the rate of decline may be lower owing to strong physician preference for Keytruda.
Another important aspect to consider is the pipeline valuation. Here’s an example of how it is done. |
17641 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. While biosimilar launches will impact Keytruda’s sales in 2028, the rate of decline may be lower owing to strong physician preference for Keytruda.
Another important aspect to consider is the pipeline valuation. Here’s an example of how it is done. For instance, Biogen (and Eisai’s) Leqembi for Alzheimer’s (AD) is expected to generate peak sales of $7 billion by 2030. |
17642 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
The Allergan acquisition, funded out of the cash flows from Humira as a replacement for Humira, can cushion the patent loss to an extent.
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. While biosimilar launches will impact Keytruda’s sales in 2028, the rate of decline may be lower owing to strong physician preference for Keytruda.
Another important aspect to consider is the pipeline valuation. Here’s an example of how it is done. For instance, Biogen (and Eisai’s) Leqembi for Alzheimer’s (AD) is expected to generate peak sales of $7 billion by 2030. It has announced a list price of $26,500 for annual course and we assumed 50 per cent rebate to insurers on average here. |
17643 | Merck, Novo Nordisk, Gilead, Biogen and more: Here are the investment opportunities in global Big Pharma
Analyst focus for Merck (12 times FY24 EPS) will start shifting to Keytruda’s likely patent loss in 2028. Despite the overhang, investors can accumulate the stock on dips. The deep pipeline powered by Keytruda combinations in immunology, ADC and other cancers, and the balance sheet strength should support Merck’s stock. While biosimilar launches will impact Keytruda’s sales in 2028, the rate of decline may be lower owing to strong physician preference for Keytruda.
Another important aspect to consider is the pipeline valuation. Here’s an example of how it is done. For instance, Biogen (and Eisai’s) Leqembi for Alzheimer’s (AD) is expected to generate peak sales of $7 billion by 2030. It has announced a list price of $26,500 for annual course and we assumed 50 per cent rebate to insurers on average here. Considering the 6 million patients in AD in the US, assuming 50 per cent are mild to moderate (applicable group according to FDA label) and 15 per cent on treatment by year 7, the drug alone can rake in $12 billion (halved to account for Eisai’s share) by 2030 in cumulative sales for a company whose market cap is $33 billion trading at 14 times FY24 EPS. |
17644 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Chris Goulding has fired off a season-high seven three-pointers to steer NBL ladder leaders Melbourne United to a 96-84 win over the Illawarra Hawks.
Operating without injured guards Ian Clark (hamstring) and Matthew Dellavedova (concussion) on Sunday, Melbourne suffered a first-half scare when Luke Travers was forced off after a knock to his left knee.
It came as visitors Illawarra surged as much as 10 points clear during a high-scoring first half at John Cain Arena.
Facebook Twitter Whatsapp Reddit Email Share
But United captain Goulding’s hot hand kept his team in the contest as he drained 21 first-half points, including five three-pointers.
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home. |
17645 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Chris Goulding has fired off a season-high seven three-pointers to steer NBL ladder leaders Melbourne United to a 96-84 win over the Illawarra Hawks.
Operating without injured guards Ian Clark (hamstring) and Matthew Dellavedova (concussion) on Sunday, Melbourne suffered a first-half scare when Luke Travers was forced off after a knock to his left knee.
It came as visitors Illawarra surged as much as 10 points clear during a high-scoring first half at John Cain Arena.
Facebook Twitter Whatsapp Reddit Email Share
But United captain Goulding’s hot hand kept his team in the contest as he drained 21 first-half points, including five three-pointers.
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home.
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne. |
17646 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Chris Goulding has fired off a season-high seven three-pointers to steer NBL ladder leaders Melbourne United to a 96-84 win over the Illawarra Hawks.
Operating without injured guards Ian Clark (hamstring) and Matthew Dellavedova (concussion) on Sunday, Melbourne suffered a first-half scare when Luke Travers was forced off after a knock to his left knee.
It came as visitors Illawarra surged as much as 10 points clear during a high-scoring first half at John Cain Arena.
Facebook Twitter Whatsapp Reddit Email Share
But United captain Goulding’s hot hand kept his team in the contest as he drained 21 first-half points, including five three-pointers.
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home.
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder. |
17647 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Operating without injured guards Ian Clark (hamstring) and Matthew Dellavedova (concussion) on Sunday, Melbourne suffered a first-half scare when Luke Travers was forced off after a knock to his left knee.
It came as visitors Illawarra surged as much as 10 points clear during a high-scoring first half at John Cain Arena.
Facebook Twitter Whatsapp Reddit Email Share
But United captain Goulding’s hot hand kept his team in the contest as he drained 21 first-half points, including five three-pointers.
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home.
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns. |
17648 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
It came as visitors Illawarra surged as much as 10 points clear during a high-scoring first half at John Cain Arena.
Facebook Twitter Whatsapp Reddit Email Share
But United captain Goulding’s hot hand kept his team in the contest as he drained 21 first-half points, including five three-pointers.
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home.
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season. |
17649 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Facebook Twitter Whatsapp Reddit Email Share
But United captain Goulding’s hot hand kept his team in the contest as he drained 21 first-half points, including five three-pointers.
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home.
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point. |
17650 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Goulding finished with 33 points including seven triples – more than any other player in a game this season – as United’s tough defence in the second half carried them home.
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point.
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury. |
17651 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point.
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury.
But Goulding caught fire to lead United to a 52-51 at the main break. |
17652 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Shea Ili (17 points) and Tanner Krebs (14) also reached double figures for Melbourne.
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point.
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury.
But Goulding caught fire to lead United to a 52-51 at the main break.
Defence was key in the second half as both sides tightened up, with Melbourne holding the visitors to just 15 points in the final period. |
17653 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The result extended United’s winning streak to six games, giving them an 8-1 record on top of the ladder.
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point.
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury.
But Goulding caught fire to lead United to a 52-51 at the main break.
Defence was key in the second half as both sides tightened up, with Melbourne holding the visitors to just 15 points in the final period.
Travers returned after half-time, finishing with six points and a game-high 11 rebounds. |
17654 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Import forward Gary Clark (24 points) and Justin Robinson (20) tried to give Illawarra a lift but Tyler Harvey managed just 10 points, three days after his clutch three-pointer sealed a thrilling win over Cairns.
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point.
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury.
But Goulding caught fire to lead United to a 52-51 at the main break.
Defence was key in the second half as both sides tightened up, with Melbourne holding the visitors to just 15 points in the final period.
Travers returned after half-time, finishing with six points and a game-high 11 rebounds.
Advertisement
Ariel Hukporti retained his spot in Melbourne’s starting five ahead of Jo Lual-Acuil Jr and impressed with seven points and 10 rebounds, including four on the offensive end. |
17655 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Advertisement
In a sloppy start, United committed five turnovers in the first period and trailed at quarter-time for the first time this season.
Clark’s eight points on perfect shooting led Illawarra to a 29-24 advantage at that point.
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury.
But Goulding caught fire to lead United to a 52-51 at the main break.
Defence was key in the second half as both sides tightened up, with Melbourne holding the visitors to just 15 points in the final period.
Travers returned after half-time, finishing with six points and a game-high 11 rebounds.
Advertisement
Ariel Hukporti retained his spot in Melbourne’s starting five ahead of Jo Lual-Acuil Jr and impressed with seven points and 10 rebounds, including four on the offensive end.
Bullets ride late luck to win over Tasmania
Nathan Sobey has peeled off a game-high 28 points as Brisbane survived a late Tasmania fightback to continue their NBL resurgence with a tense 90-87 win. |
17656 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
His tally swelled to 16 by the main break and the Hawks’ lead reached double figures soon after United temporarily lost Travers to injury.
But Goulding caught fire to lead United to a 52-51 at the main break.
Defence was key in the second half as both sides tightened up, with Melbourne holding the visitors to just 15 points in the final period.
Travers returned after half-time, finishing with six points and a game-high 11 rebounds.
Advertisement
Ariel Hukporti retained his spot in Melbourne’s starting five ahead of Jo Lual-Acuil Jr and impressed with seven points and 10 rebounds, including four on the offensive end.
Bullets ride late luck to win over Tasmania
Nathan Sobey has peeled off a game-high 28 points as Brisbane survived a late Tasmania fightback to continue their NBL resurgence with a tense 90-87 win.
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process. |
17657 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
But Goulding caught fire to lead United to a 52-51 at the main break.
Defence was key in the second half as both sides tightened up, with Melbourne holding the visitors to just 15 points in the final period.
Travers returned after half-time, finishing with six points and a game-high 11 rebounds.
Advertisement
Ariel Hukporti retained his spot in Melbourne’s starting five ahead of Jo Lual-Acuil Jr and impressed with seven points and 10 rebounds, including four on the offensive end.
Bullets ride late luck to win over Tasmania
Nathan Sobey has peeled off a game-high 28 points as Brisbane survived a late Tasmania fightback to continue their NBL resurgence with a tense 90-87 win.
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process.
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season. |
17658 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Travers returned after half-time, finishing with six points and a game-high 11 rebounds.
Advertisement
Ariel Hukporti retained his spot in Melbourne’s starting five ahead of Jo Lual-Acuil Jr and impressed with seven points and 10 rebounds, including four on the offensive end.
Bullets ride late luck to win over Tasmania
Nathan Sobey has peeled off a game-high 28 points as Brisbane survived a late Tasmania fightback to continue their NBL resurgence with a tense 90-87 win.
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process.
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season.
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds. |
17659 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Travers returned after half-time, finishing with six points and a game-high 11 rebounds.
Advertisement
Ariel Hukporti retained his spot in Melbourne’s starting five ahead of Jo Lual-Acuil Jr and impressed with seven points and 10 rebounds, including four on the offensive end.
Bullets ride late luck to win over Tasmania
Nathan Sobey has peeled off a game-high 28 points as Brisbane survived a late Tasmania fightback to continue their NBL resurgence with a tense 90-87 win.
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process.
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season.
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds.
But it didn’t come easily as fourth-quarter specialists Tasmania trimmed a seven-point deficit back to a single point when Majok Deng drove to the rack with 34 seconds remaining. |
17660 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Bullets ride late luck to win over Tasmania
Nathan Sobey has peeled off a game-high 28 points as Brisbane survived a late Tasmania fightback to continue their NBL resurgence with a tense 90-87 win.
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process.
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season.
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds.
But it didn’t come easily as fourth-quarter specialists Tasmania trimmed a seven-point deficit back to a single point when Majok Deng drove to the rack with 34 seconds remaining.
Advertisement
The two sides traded blows in the dying stages and the JackJumpers almost sent the game to overtime when they pinched Sam McDaniel’s inbounds pass on the final play. |
17661 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process.
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season.
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds.
But it didn’t come easily as fourth-quarter specialists Tasmania trimmed a seven-point deficit back to a single point when Majok Deng drove to the rack with 34 seconds remaining.
Advertisement
The two sides traded blows in the dying stages and the JackJumpers almost sent the game to overtime when they pinched Sam McDaniel’s inbounds pass on the final play.
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out. |
17662 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Despite being without star big Aron Baynes (suspended) and import guard Shannon Scott (hamstring), the Bullets soared to a second straight victory on Sunday and snapped a quirky streak in the process.
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season.
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds.
But it didn’t come easily as fourth-quarter specialists Tasmania trimmed a seven-point deficit back to a single point when Majok Deng drove to the rack with 34 seconds remaining.
Advertisement
The two sides traded blows in the dying stages and the JackJumpers almost sent the game to overtime when they pinched Sam McDaniel’s inbounds pass on the final play.
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out.
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough. |
17663 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
It was their first win after seven straight losses in Sunday fixtures, in a run that dates back to last season.
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds.
But it didn’t come easily as fourth-quarter specialists Tasmania trimmed a seven-point deficit back to a single point when Majok Deng drove to the rack with 34 seconds remaining.
Advertisement
The two sides traded blows in the dying stages and the JackJumpers almost sent the game to overtime when they pinched Sam McDaniel’s inbounds pass on the final play.
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out.
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough.
Brisbane captain Sobey led from the front as defensive specialist Mitch Norton kept Tasmania’s import Crawford (16 points) relatively quiet until the final period. |
17664 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Far more importantly, the result levelled Brisbane’s current season record at 4-4 after five rounds.
But it didn’t come easily as fourth-quarter specialists Tasmania trimmed a seven-point deficit back to a single point when Majok Deng drove to the rack with 34 seconds remaining.
Advertisement
The two sides traded blows in the dying stages and the JackJumpers almost sent the game to overtime when they pinched Sam McDaniel’s inbounds pass on the final play.
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out.
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough.
Brisbane captain Sobey led from the front as defensive specialist Mitch Norton kept Tasmania’s import Crawford (16 points) relatively quiet until the final period.
Tyrrell Harrison and Josh Bannan (10 points each) were important for the Bullets, while Chris Smith (11) and Isaac White (10) gave solid contributions off the bench. |
17665 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Advertisement
The two sides traded blows in the dying stages and the JackJumpers almost sent the game to overtime when they pinched Sam McDaniel’s inbounds pass on the final play.
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out.
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough.
Brisbane captain Sobey led from the front as defensive specialist Mitch Norton kept Tasmania’s import Crawford (16 points) relatively quiet until the final period.
Tyrrell Harrison and Josh Bannan (10 points each) were important for the Bullets, while Chris Smith (11) and Isaac White (10) gave solid contributions off the bench.
The gut-wrenching loss ended a horror round five for the JackJumpers, who lost at home to Melbourne United before going down to the Bullets. |
17666 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out.
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough.
Brisbane captain Sobey led from the front as defensive specialist Mitch Norton kept Tasmania’s import Crawford (16 points) relatively quiet until the final period.
Tyrrell Harrison and Josh Bannan (10 points each) were important for the Bullets, while Chris Smith (11) and Isaac White (10) gave solid contributions off the bench.
The gut-wrenching loss ended a horror round five for the JackJumpers, who lost at home to Melbourne United before going down to the Bullets.
Advertisement
It left them with a 4-4 record after a strong 4-2 start to the season. |
17667 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Jack McVeigh got a hand in to force the turnover and Tasmania found Jordon Crawford, but his decent look at an attempted game-leveller rimmed out.
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough.
Brisbane captain Sobey led from the front as defensive specialist Mitch Norton kept Tasmania’s import Crawford (16 points) relatively quiet until the final period.
Tyrrell Harrison and Josh Bannan (10 points each) were important for the Bullets, while Chris Smith (11) and Isaac White (10) gave solid contributions off the bench.
The gut-wrenching loss ended a horror round five for the JackJumpers, who lost at home to Melbourne United before going down to the Bullets.
Advertisement
It left them with a 4-4 record after a strong 4-2 start to the season.
McVeigh (18 points) and Deng (17) gave strong offensive contributions for Tasmania, who lost Marcus Lee for the final few minutes after the starting centre fouled out. |
17668 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The JackJumpers, who trailed by seven at three-quarter time, kept alive their record of winning every fourth term this season, but it wasn’t enough.
Brisbane captain Sobey led from the front as defensive specialist Mitch Norton kept Tasmania’s import Crawford (16 points) relatively quiet until the final period.
Tyrrell Harrison and Josh Bannan (10 points each) were important for the Bullets, while Chris Smith (11) and Isaac White (10) gave solid contributions off the bench.
The gut-wrenching loss ended a horror round five for the JackJumpers, who lost at home to Melbourne United before going down to the Bullets.
Advertisement
It left them with a 4-4 record after a strong 4-2 start to the season.
McVeigh (18 points) and Deng (17) gave strong offensive contributions for Tasmania, who lost Marcus Lee for the final few minutes after the starting centre fouled out.
Taipans import injured in win over Kings
A nasty back injury to first-year import sensation Patrick Miller has marred the Taipans’ otherwise impressive 87-80 win over Sydney at the Cairns Convention Centre. |
17669 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Tyrrell Harrison and Josh Bannan (10 points each) were important for the Bullets, while Chris Smith (11) and Isaac White (10) gave solid contributions off the bench.
The gut-wrenching loss ended a horror round five for the JackJumpers, who lost at home to Melbourne United before going down to the Bullets.
Advertisement
It left them with a 4-4 record after a strong 4-2 start to the season.
McVeigh (18 points) and Deng (17) gave strong offensive contributions for Tasmania, who lost Marcus Lee for the final few minutes after the starting centre fouled out.
Taipans import injured in win over Kings
A nasty back injury to first-year import sensation Patrick Miller has marred the Taipans’ otherwise impressive 87-80 win over Sydney at the Cairns Convention Centre.
Miller, who entered Saturday night’s clash ranked second in the NBL in scoring and fourth in assists, had the hosts in control before an explosive drive to the bucket ended with him crashing to the floor, 1:09 out from halftime. |
17670 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The gut-wrenching loss ended a horror round five for the JackJumpers, who lost at home to Melbourne United before going down to the Bullets.
Advertisement
It left them with a 4-4 record after a strong 4-2 start to the season.
McVeigh (18 points) and Deng (17) gave strong offensive contributions for Tasmania, who lost Marcus Lee for the final few minutes after the starting centre fouled out.
Taipans import injured in win over Kings
A nasty back injury to first-year import sensation Patrick Miller has marred the Taipans’ otherwise impressive 87-80 win over Sydney at the Cairns Convention Centre.
Miller, who entered Saturday night’s clash ranked second in the NBL in scoring and fourth in assists, had the hosts in control before an explosive drive to the bucket ended with him crashing to the floor, 1:09 out from halftime.
The American’s head whip-lashed onto the floor before he got up gingerly and walked slowly to the bench holding his lower back, unable to continue. |
17671 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Advertisement
It left them with a 4-4 record after a strong 4-2 start to the season.
McVeigh (18 points) and Deng (17) gave strong offensive contributions for Tasmania, who lost Marcus Lee for the final few minutes after the starting centre fouled out.
Taipans import injured in win over Kings
A nasty back injury to first-year import sensation Patrick Miller has marred the Taipans’ otherwise impressive 87-80 win over Sydney at the Cairns Convention Centre.
Miller, who entered Saturday night’s clash ranked second in the NBL in scoring and fourth in assists, had the hosts in control before an explosive drive to the bucket ended with him crashing to the floor, 1:09 out from halftime.
The American’s head whip-lashed onto the floor before he got up gingerly and walked slowly to the bench holding his lower back, unable to continue.
Stepping up were acting skipper Bul Kuol (24, played all 40 minutes) and big Sam Waardenburg (22) for the Snakes, who shrugged off last Thursday’s buzzer-beating heartbreak in Illawarra by taking the NBL’s most prized scalp. |
17672 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Taipans import injured in win over Kings
A nasty back injury to first-year import sensation Patrick Miller has marred the Taipans’ otherwise impressive 87-80 win over Sydney at the Cairns Convention Centre.
Miller, who entered Saturday night’s clash ranked second in the NBL in scoring and fourth in assists, had the hosts in control before an explosive drive to the bucket ended with him crashing to the floor, 1:09 out from halftime.
The American’s head whip-lashed onto the floor before he got up gingerly and walked slowly to the bench holding his lower back, unable to continue.
Stepping up were acting skipper Bul Kuol (24, played all 40 minutes) and big Sam Waardenburg (22) for the Snakes, who shrugged off last Thursday’s buzzer-beating heartbreak in Illawarra by taking the NBL’s most prized scalp.
Advertisement
It shot them from fifth to third on the ladder, while sending the Kings slumping from second to fourth. |
17673 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Miller, who entered Saturday night’s clash ranked second in the NBL in scoring and fourth in assists, had the hosts in control before an explosive drive to the bucket ended with him crashing to the floor, 1:09 out from halftime.
The American’s head whip-lashed onto the floor before he got up gingerly and walked slowly to the bench holding his lower back, unable to continue.
Stepping up were acting skipper Bul Kuol (24, played all 40 minutes) and big Sam Waardenburg (22) for the Snakes, who shrugged off last Thursday’s buzzer-beating heartbreak in Illawarra by taking the NBL’s most prized scalp.
Advertisement
It shot them from fifth to third on the ladder, while sending the Kings slumping from second to fourth.
“We kept moving down the bench to bring guys in,” Cairns coach Adam Forde said. “Everyone responded. |
17674 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Miller, who entered Saturday night’s clash ranked second in the NBL in scoring and fourth in assists, had the hosts in control before an explosive drive to the bucket ended with him crashing to the floor, 1:09 out from halftime.
The American’s head whip-lashed onto the floor before he got up gingerly and walked slowly to the bench holding his lower back, unable to continue.
Stepping up were acting skipper Bul Kuol (24, played all 40 minutes) and big Sam Waardenburg (22) for the Snakes, who shrugged off last Thursday’s buzzer-beating heartbreak in Illawarra by taking the NBL’s most prized scalp.
Advertisement
It shot them from fifth to third on the ladder, while sending the Kings slumping from second to fourth.
“We kept moving down the bench to bring guys in,” Cairns coach Adam Forde said. “Everyone responded.
“I’m super happy for the group that they could fill some short-term reward with a win at home.”
Ex-Taipan Kouat Noi (18 points) top-scored for the visitors, while Jaylen Adams (13) and DJ Hogg (13) – playing against his former side in his long-awaited debut for his new team following a shoulder injury – got on the scoresheet, but both shot under 30 per cent, embodying the Kings’ rocky evening. |
17675 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Advertisement
It shot them from fifth to third on the ladder, while sending the Kings slumping from second to fourth.
“We kept moving down the bench to bring guys in,” Cairns coach Adam Forde said. “Everyone responded.
“I’m super happy for the group that they could fill some short-term reward with a win at home.”
Ex-Taipan Kouat Noi (18 points) top-scored for the visitors, while Jaylen Adams (13) and DJ Hogg (13) – playing against his former side in his long-awaited debut for his new team following a shoulder injury – got on the scoresheet, but both shot under 30 per cent, embodying the Kings’ rocky evening.
The two-time reigning champions were all at sea early, out-rebounded 18-6 in the opening term while missing their first 15 three-pointers. |
17676 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Advertisement
It shot them from fifth to third on the ladder, while sending the Kings slumping from second to fourth.
“We kept moving down the bench to bring guys in,” Cairns coach Adam Forde said. “Everyone responded.
“I’m super happy for the group that they could fill some short-term reward with a win at home.”
Ex-Taipan Kouat Noi (18 points) top-scored for the visitors, while Jaylen Adams (13) and DJ Hogg (13) – playing against his former side in his long-awaited debut for his new team following a shoulder injury – got on the scoresheet, but both shot under 30 per cent, embodying the Kings’ rocky evening.
The two-time reigning champions were all at sea early, out-rebounded 18-6 in the opening term while missing their first 15 three-pointers.
Cairns boosted their 26-20 quarter-time buffer to 12 points shortly before Miller’s night ended in stomach-churning style. |
17677 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
“We kept moving down the bench to bring guys in,” Cairns coach Adam Forde said. “Everyone responded.
“I’m super happy for the group that they could fill some short-term reward with a win at home.”
Ex-Taipan Kouat Noi (18 points) top-scored for the visitors, while Jaylen Adams (13) and DJ Hogg (13) – playing against his former side in his long-awaited debut for his new team following a shoulder injury – got on the scoresheet, but both shot under 30 per cent, embodying the Kings’ rocky evening.
The two-time reigning champions were all at sea early, out-rebounded 18-6 in the opening term while missing their first 15 three-pointers.
Cairns boosted their 26-20 quarter-time buffer to 12 points shortly before Miller’s night ended in stomach-churning style.
Advertisement
The injury left their backcourt stocks further depleted, with Taran Armstrong (foot) and captain Tahjere McCall (family reasons) already missing. |
17678 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
“Everyone responded.
“I’m super happy for the group that they could fill some short-term reward with a win at home.”
Ex-Taipan Kouat Noi (18 points) top-scored for the visitors, while Jaylen Adams (13) and DJ Hogg (13) – playing against his former side in his long-awaited debut for his new team following a shoulder injury – got on the scoresheet, but both shot under 30 per cent, embodying the Kings’ rocky evening.
The two-time reigning champions were all at sea early, out-rebounded 18-6 in the opening term while missing their first 15 three-pointers.
Cairns boosted their 26-20 quarter-time buffer to 12 points shortly before Miller’s night ended in stomach-churning style.
Advertisement
The injury left their backcourt stocks further depleted, with Taran Armstrong (foot) and captain Tahjere McCall (family reasons) already missing.
Without Miller running the point, the home side’s offence suddenly looked shaky in the third term as Sydney briefly took the lead on a Hogg triple. |
17679 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The two-time reigning champions were all at sea early, out-rebounded 18-6 in the opening term while missing their first 15 three-pointers.
Cairns boosted their 26-20 quarter-time buffer to 12 points shortly before Miller’s night ended in stomach-churning style.
Advertisement
The injury left their backcourt stocks further depleted, with Taran Armstrong (foot) and captain Tahjere McCall (family reasons) already missing.
Without Miller running the point, the home side’s offence suddenly looked shaky in the third term as Sydney briefly took the lead on a Hogg triple.
The undermanned Taipans responded with a 15-0 burst either side of three-quarter time, highlighted by Swedish young gun Bobi Klintman’s thunderous dunk down the middle over rival Next Star Alex Toohey. |
17680 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The two-time reigning champions were all at sea early, out-rebounded 18-6 in the opening term while missing their first 15 three-pointers.
Cairns boosted their 26-20 quarter-time buffer to 12 points shortly before Miller’s night ended in stomach-churning style.
Advertisement
The injury left their backcourt stocks further depleted, with Taran Armstrong (foot) and captain Tahjere McCall (family reasons) already missing.
Without Miller running the point, the home side’s offence suddenly looked shaky in the third term as Sydney briefly took the lead on a Hogg triple.
The undermanned Taipans responded with a 15-0 burst either side of three-quarter time, highlighted by Swedish young gun Bobi Klintman’s thunderous dunk down the middle over rival Next Star Alex Toohey.
Down by 14, Sydney closed the gap to four points before unsportsmanlike fouls against Denzel Valentine and Makuach Maluach ended their revival. |
17681 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Cairns boosted their 26-20 quarter-time buffer to 12 points shortly before Miller’s night ended in stomach-churning style.
Advertisement
The injury left their backcourt stocks further depleted, with Taran Armstrong (foot) and captain Tahjere McCall (family reasons) already missing.
Without Miller running the point, the home side’s offence suddenly looked shaky in the third term as Sydney briefly took the lead on a Hogg triple.
The undermanned Taipans responded with a 15-0 burst either side of three-quarter time, highlighted by Swedish young gun Bobi Klintman’s thunderous dunk down the middle over rival Next Star Alex Toohey.
Down by 14, Sydney closed the gap to four points before unsportsmanlike fouls against Denzel Valentine and Makuach Maluach ended their revival.
Lamenting “the defensive mistakes that we made”, Kings coach Mahmoud Abdelfattah added: “They made more plays than we did, they got to the 50/50 balls and they stuck together. |
17682 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Advertisement
The injury left their backcourt stocks further depleted, with Taran Armstrong (foot) and captain Tahjere McCall (family reasons) already missing.
Without Miller running the point, the home side’s offence suddenly looked shaky in the third term as Sydney briefly took the lead on a Hogg triple.
The undermanned Taipans responded with a 15-0 burst either side of three-quarter time, highlighted by Swedish young gun Bobi Klintman’s thunderous dunk down the middle over rival Next Star Alex Toohey.
Down by 14, Sydney closed the gap to four points before unsportsmanlike fouls against Denzel Valentine and Makuach Maluach ended their revival.
Lamenting “the defensive mistakes that we made”, Kings coach Mahmoud Abdelfattah added: “They made more plays than we did, they got to the 50/50 balls and they stuck together.
“Kudos to them, they deserved it.”
Advertisement
Phoenix hold off fast-finishing Breakers
South East Melbourne Phoenix have survived a massive late scare to clinch a tense 103-100 victory over the fast-finishing New Zealand Breakers at John Cain Arena. |
17683 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The undermanned Taipans responded with a 15-0 burst either side of three-quarter time, highlighted by Swedish young gun Bobi Klintman’s thunderous dunk down the middle over rival Next Star Alex Toohey.
Down by 14, Sydney closed the gap to four points before unsportsmanlike fouls against Denzel Valentine and Makuach Maluach ended their revival.
Lamenting “the defensive mistakes that we made”, Kings coach Mahmoud Abdelfattah added: “They made more plays than we did, they got to the 50/50 balls and they stuck together.
“Kudos to them, they deserved it.”
Advertisement
Phoenix hold off fast-finishing Breakers
South East Melbourne Phoenix have survived a massive late scare to clinch a tense 103-100 victory over the fast-finishing New Zealand Breakers at John Cain Arena.
The Phoenix were eyeing off a percentage pile-on when they led by a whopping 26 points on Saturday before the bottom-placed, injury-hit Breakers produced a brave rearguard to almost pinch a miracle. |
17684 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Down by 14, Sydney closed the gap to four points before unsportsmanlike fouls against Denzel Valentine and Makuach Maluach ended their revival.
Lamenting “the defensive mistakes that we made”, Kings coach Mahmoud Abdelfattah added: “They made more plays than we did, they got to the 50/50 balls and they stuck together.
“Kudos to them, they deserved it.”
Advertisement
Phoenix hold off fast-finishing Breakers
South East Melbourne Phoenix have survived a massive late scare to clinch a tense 103-100 victory over the fast-finishing New Zealand Breakers at John Cain Arena.
The Phoenix were eyeing off a percentage pile-on when they led by a whopping 26 points on Saturday before the bottom-placed, injury-hit Breakers produced a brave rearguard to almost pinch a miracle.
The Phoenix’s big four – Alan Williams (21 points, 13 rebounds), Mitch Creek (20 points), Gary Browne (18 points, eight assists) and Will Cummings (16 points, all in the first half) – led the way but the final stages got too close for comfort. |
17685 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Lamenting “the defensive mistakes that we made”, Kings coach Mahmoud Abdelfattah added: “They made more plays than we did, they got to the 50/50 balls and they stuck together.
“Kudos to them, they deserved it.”
Advertisement
Phoenix hold off fast-finishing Breakers
South East Melbourne Phoenix have survived a massive late scare to clinch a tense 103-100 victory over the fast-finishing New Zealand Breakers at John Cain Arena.
The Phoenix were eyeing off a percentage pile-on when they led by a whopping 26 points on Saturday before the bottom-placed, injury-hit Breakers produced a brave rearguard to almost pinch a miracle.
The Phoenix’s big four – Alan Williams (21 points, 13 rebounds), Mitch Creek (20 points), Gary Browne (18 points, eight assists) and Will Cummings (16 points, all in the first half) – led the way but the final stages got too close for comfort.
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat. |
17686 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The Phoenix were eyeing off a percentage pile-on when they led by a whopping 26 points on Saturday before the bottom-placed, injury-hit Breakers produced a brave rearguard to almost pinch a miracle.
The Phoenix’s big four – Alan Williams (21 points, 13 rebounds), Mitch Creek (20 points), Gary Browne (18 points, eight assists) and Will Cummings (16 points, all in the first half) – led the way but the final stages got too close for comfort.
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat.
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. |
17687 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The Phoenix were eyeing off a percentage pile-on when they led by a whopping 26 points on Saturday before the bottom-placed, injury-hit Breakers produced a brave rearguard to almost pinch a miracle.
The Phoenix’s big four – Alan Williams (21 points, 13 rebounds), Mitch Creek (20 points), Gary Browne (18 points, eight assists) and Will Cummings (16 points, all in the first half) – led the way but the final stages got too close for comfort.
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat.
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. “Our guys are doing everything they can and everything I ask of them everyday. |
17688 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The Phoenix were eyeing off a percentage pile-on when they led by a whopping 26 points on Saturday before the bottom-placed, injury-hit Breakers produced a brave rearguard to almost pinch a miracle.
The Phoenix’s big four – Alan Williams (21 points, 13 rebounds), Mitch Creek (20 points), Gary Browne (18 points, eight assists) and Will Cummings (16 points, all in the first half) – led the way but the final stages got too close for comfort.
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat.
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. “Our guys are doing everything they can and everything I ask of them everyday. “They are working as hard as can be. |
17689 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
The Phoenix’s big four – Alan Williams (21 points, 13 rebounds), Mitch Creek (20 points), Gary Browne (18 points, eight assists) and Will Cummings (16 points, all in the first half) – led the way but the final stages got too close for comfort.
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat.
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. “Our guys are doing everything they can and everything I ask of them everyday. “They are working as hard as can be. Our fans should be proud of the level of effort our guys put in.”
Advertisement
They were without import power forward Zylan Cheatham, who suffered a broken foot in last Thursday’s loss to Adelaide, and Williams duly proved a beast in the low block against the undersized Anthony Lamb. |
17690 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat.
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. “Our guys are doing everything they can and everything I ask of them everyday. “They are working as hard as can be. Our fans should be proud of the level of effort our guys put in.”
Advertisement
They were without import power forward Zylan Cheatham, who suffered a broken foot in last Thursday’s loss to Adelaide, and Williams duly proved a beast in the low block against the undersized Anthony Lamb.
Behind Williams’ dominance and Browne’s ball-handling and playmaking wizardry, the Phoenix pulled ahead 31-21 at quarter-time. |
17691 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Electrifying American point guard Parker Jackson-Cartwright (33 points, eight assists) and Finn Delany (21 points) were instrumental in the 32-19 fourth-quarter fightback from the Breakers, who were brave despite succumbing to their fourth successive defeat.
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. “Our guys are doing everything they can and everything I ask of them everyday. “They are working as hard as can be. Our fans should be proud of the level of effort our guys put in.”
Advertisement
They were without import power forward Zylan Cheatham, who suffered a broken foot in last Thursday’s loss to Adelaide, and Williams duly proved a beast in the low block against the undersized Anthony Lamb.
Behind Williams’ dominance and Browne’s ball-handling and playmaking wizardry, the Phoenix pulled ahead 31-21 at quarter-time.
Cummings scored at will in the second stanza before Creek inspired a 16-0 third-quarter burst for the home side, whose advantage swelled to 80-54. |
17692 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
“We were one lucky bounce away from winning this game,” NZ coach Mody Maor said. “Our guys are doing everything they can and everything I ask of them everyday. “They are working as hard as can be. Our fans should be proud of the level of effort our guys put in.”
Advertisement
They were without import power forward Zylan Cheatham, who suffered a broken foot in last Thursday’s loss to Adelaide, and Williams duly proved a beast in the low block against the undersized Anthony Lamb.
Behind Williams’ dominance and Browne’s ball-handling and playmaking wizardry, the Phoenix pulled ahead 31-21 at quarter-time.
Cummings scored at will in the second stanza before Creek inspired a 16-0 third-quarter burst for the home side, whose advantage swelled to 80-54.
NZ reverted to a zone defence and centre Mangok Mathiang impacted at both ends as the Breakers went 17-2 either side of three-quarter-time to haul themselves back into the contest. |
17693 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
“Our guys are doing everything they can and everything I ask of them everyday. “They are working as hard as can be. Our fans should be proud of the level of effort our guys put in.”
Advertisement
They were without import power forward Zylan Cheatham, who suffered a broken foot in last Thursday’s loss to Adelaide, and Williams duly proved a beast in the low block against the undersized Anthony Lamb.
Behind Williams’ dominance and Browne’s ball-handling and playmaking wizardry, the Phoenix pulled ahead 31-21 at quarter-time.
Cummings scored at will in the second stanza before Creek inspired a 16-0 third-quarter burst for the home side, whose advantage swelled to 80-54.
NZ reverted to a zone defence and centre Mangok Mathiang impacted at both ends as the Breakers went 17-2 either side of three-quarter-time to haul themselves back into the contest.
Quicksilver Cartwright-Jackson poured in 10 points inside three minutes to reduce the margin to three points down the stretch before Williams’ hook and Browne’s free throw iced it narrowly. |
17694 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Behind Williams’ dominance and Browne’s ball-handling and playmaking wizardry, the Phoenix pulled ahead 31-21 at quarter-time.
Cummings scored at will in the second stanza before Creek inspired a 16-0 third-quarter burst for the home side, whose advantage swelled to 80-54.
NZ reverted to a zone defence and centre Mangok Mathiang impacted at both ends as the Breakers went 17-2 either side of three-quarter-time to haul themselves back into the contest.
Quicksilver Cartwright-Jackson poured in 10 points inside three minutes to reduce the margin to three points down the stretch before Williams’ hook and Browne’s free throw iced it narrowly.
“It was frustrating to see the lead dwindle,” Phoenix coach Mike Kelly said. “But it’s a win. The guys are going in the right direction. |
17695 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Behind Williams’ dominance and Browne’s ball-handling and playmaking wizardry, the Phoenix pulled ahead 31-21 at quarter-time.
Cummings scored at will in the second stanza before Creek inspired a 16-0 third-quarter burst for the home side, whose advantage swelled to 80-54.
NZ reverted to a zone defence and centre Mangok Mathiang impacted at both ends as the Breakers went 17-2 either side of three-quarter-time to haul themselves back into the contest.
Quicksilver Cartwright-Jackson poured in 10 points inside three minutes to reduce the margin to three points down the stretch before Williams’ hook and Browne’s free throw iced it narrowly.
“It was frustrating to see the lead dwindle,” Phoenix coach Mike Kelly said. “But it’s a win. The guys are going in the right direction. “I’m not disappointed, I’m stoked.”
Bullets shoot down weakened Wildcats
Advertisement
The Brisbane Bullets have shrugged off the absence of two important players to outwork the Wildcats at their home RAC Arena in Perth and produce a performance full of heart for their 84-79 NBL win. |
17696 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
NZ reverted to a zone defence and centre Mangok Mathiang impacted at both ends as the Breakers went 17-2 either side of three-quarter-time to haul themselves back into the contest.
Quicksilver Cartwright-Jackson poured in 10 points inside three minutes to reduce the margin to three points down the stretch before Williams’ hook and Browne’s free throw iced it narrowly.
“It was frustrating to see the lead dwindle,” Phoenix coach Mike Kelly said. “But it’s a win. The guys are going in the right direction. “I’m not disappointed, I’m stoked.”
Bullets shoot down weakened Wildcats
Advertisement
The Brisbane Bullets have shrugged off the absence of two important players to outwork the Wildcats at their home RAC Arena in Perth and produce a performance full of heart for their 84-79 NBL win.
Both teams were 2-4 coming into Friday’s match and on losing slides, but it was the Wildcats who had the pressure building, even with the Bullets being without key pair, the suspended Aron Baynes and injured Shannon Scott. |
17697 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
Quicksilver Cartwright-Jackson poured in 10 points inside three minutes to reduce the margin to three points down the stretch before Williams’ hook and Browne’s free throw iced it narrowly.
“It was frustrating to see the lead dwindle,” Phoenix coach Mike Kelly said. “But it’s a win. The guys are going in the right direction. “I’m not disappointed, I’m stoked.”
Bullets shoot down weakened Wildcats
Advertisement
The Brisbane Bullets have shrugged off the absence of two important players to outwork the Wildcats at their home RAC Arena in Perth and produce a performance full of heart for their 84-79 NBL win.
Both teams were 2-4 coming into Friday’s match and on losing slides, but it was the Wildcats who had the pressure building, even with the Bullets being without key pair, the suspended Aron Baynes and injured Shannon Scott.
Brisbane scored the first seven points before opening up a 20-point lead in the third quarter and going on to win by five after holding out against a furious late charge from the home team. |
17698 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
“It was frustrating to see the lead dwindle,” Phoenix coach Mike Kelly said. “But it’s a win. The guys are going in the right direction. “I’m not disappointed, I’m stoked.”
Bullets shoot down weakened Wildcats
Advertisement
The Brisbane Bullets have shrugged off the absence of two important players to outwork the Wildcats at their home RAC Arena in Perth and produce a performance full of heart for their 84-79 NBL win.
Both teams were 2-4 coming into Friday’s match and on losing slides, but it was the Wildcats who had the pressure building, even with the Bullets being without key pair, the suspended Aron Baynes and injured Shannon Scott.
Brisbane scored the first seven points before opening up a 20-point lead in the third quarter and going on to win by five after holding out against a furious late charge from the home team.
The team effort of the Bullets was outstanding as they got another 17 points from captain Nathan Sobey. |
17699 | NBL Round 5: Harvey hits Hail Mary for Hawks to topple Taipans at the buzzer, Cheatham injured as Sixers upset Breakers
“But it’s a win. The guys are going in the right direction. “I’m not disappointed, I’m stoked.”
Bullets shoot down weakened Wildcats
Advertisement
The Brisbane Bullets have shrugged off the absence of two important players to outwork the Wildcats at their home RAC Arena in Perth and produce a performance full of heart for their 84-79 NBL win.
Both teams were 2-4 coming into Friday’s match and on losing slides, but it was the Wildcats who had the pressure building, even with the Bullets being without key pair, the suspended Aron Baynes and injured Shannon Scott.
Brisbane scored the first seven points before opening up a 20-point lead in the third quarter and going on to win by five after holding out against a furious late charge from the home team.
The team effort of the Bullets was outstanding as they got another 17 points from captain Nathan Sobey.
Chris Smith put up 16 points, Josh Bannan 15 and Tyrell Harrison 12 to go with five rebounds and three blocks in just 14 minutes. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.